B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors

Abstract Background PD-1 inhibitors are approved for multiple malignancies and function by stimulating T cells. However, the role of B cells in the anti-tumor activity of these drugs is unknown, as is their activity in patients who have received B cell depleting drugs or with immunoglobulin deficien...

Full description

Bibliographic Details
Main Authors: William Damsky, Lucia Jilaveanu, Noel Turner, Curtis Perry, Christopher Zito, Mary Tomayko, Jonathan Leventhal, Kevan Herold, Eric Meffre, Marcus Bosenberg, Harriet M. Kluger
Format: Article
Language:English
Published: BMJ Publishing Group 2019-06-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
B cell depletion
Immune checkpoint blockade
PD-1
CD20
Melanoma
Colon cancer
Online Access:http://link.springer.com/article/10.1186/s40425-019-0613-1

Internet

http://link.springer.com/article/10.1186/s40425-019-0613-1

Similar Items